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Abstract 
 
Background: Fibromyalgia (FM) and chronic fatigue syndrome (CFS), two diseases 
that are frequently associated, are known to share many symptoms, which include pain - 
usually more pronounced in FM - and fatigue, together with mood, sleep and 
neurocognitive disorders. Symptoms as clouded mentation, forgetfulness and difficulty 
concentrating are very common and contribute to the disability of the disorders. These 
complaints are termed “fibrofog” and suggest that the central nervous system may be 
involved in the pathophysiology of the syndroms. Coexisting psychological distress or a 
psychiatric disorder also may contribute to neurocognitive deficits. Moreover literature 
data suggest that the peptide β amyloid, major constituent of amyloid plaques, is 
involved in neurodegenerative and psychiatric disorders as Alzheimer and depression. 
  
Objective: The aim of the study was to investigate neurocognitive disorders in FMS 
and CFS patients also examining the influence of many clinical variables (i.e. pain, 
fatigue, mood and sleep disorders, drug assumption). Secondary objective was to 
evaluate the levels of β amyloid to better understand neurodegenerative impairments in 
these syndromes. 
 
Methods: Forty patients with a diagnosis of fibromyalgia and 45 patients with a 
diagnosis of chronic fatigue syndrome were consecutively recruited. All patients were 
asked to complete a set of questionnaires on paper and perform a battery of 
neurocognitive computerized (CNS Vital Signs©). Subsequently in a subgroup of 25 
FMS, 25 CFS patients and 25  healthy subjects we evaluated the levels of  beta amyloid 
(isoforms Aβ 40 and Aβ 42  and their ratio) using a commercial ELISA kit. 
 
Results: Patients with fibromyalgia were compared to chronic fatigue syndrome, and in 
the first group female sex was prevalent (97.5% vs 51.1%). Moreover, they were 
different for duration of illness and pain perception. Although patients from both groups 
similarly complained about neurocognitive problems of concentration or/and attention, 
thanks to the use of CNS Vital Signs© test battery we found that fibromyalgia patients 
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resulted to have more compromised neurocognitive function and neurocognitive 
impairments were found to correlate with pain and illness duration. Concerning beta 
amyloid no difference in Aβ 40 and Aβ 42 and their ratio was found between patient 
and control, moreover we did not find any correlation between Aβ40 and Aβ42 levels 
and cognitive impairment. In the FM group we found a statistically significant negative 
correlation between Aβ40/42 ratio and disease duration (p=0.0056; r= -0.53) and a 
statistically significant negative correlation between Aβ40 levels and FIQ values 
(p=0.037; r=-0.42) and FACIT scores (p=0.0069; r=-0.52). Moreover in FM we found a 
negative correlation between Aβ42 levels and age (p=0,03, r= -0,43) 
 
Conclusion: In patient affected by fibromyalgia or/and chronic fatigue syndrome, 
neurocognitive impairments should never be underestimated, because they could 
disclose a more severe condition affecting the central nervous system. The cognitive 
impairment referred by FM and CFS patients and evaluated by CNS vital signs© don’t 
correlate with the Aβ levels. These observation suggest that the cognitive impairment 
referred by the patients, was probably related to the health status, instead of a damage of 
central nervous system. 
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Chapter 1: Introduction 
 
1. Fibromyalgia 
Fibromyalgia syndrome (FMS) is a common extra-articular rheumatic disorder 
characterized by chronic widespread musculoskeletal pain, stiffness and presence of 
multiple points tenderness to palpation (tender points). FMS affects approximately 2% 
to 5% of the population and its etiology is uncertain. It is most frequent in females aged 
20 to 50 years. Pain is the defining characteristic of FMS, it is usually described as 
fluctuating and always associated with hyperalgesia and/or allodynia but the disorder is 
frequently associated with other symptoms, such as stiffness, fatigue, anxiety, 
depression, mental confusion and sleep disturbances. Moreover patients frequently 
report diminished cognitive performance such as memory and attention deficit. 
FMS varies in severity, however quality of life in FMS patients is reduced both for 
physical and emotional involvement. Approximately 50% of all patients have difficulty 
with routine daily activities, while 30-40% have to stop work or change their 
employment. 
 
The etiology of FM has not yet been fully understood. Several authors (Kindler LL et al, 
2011; Yunus MB, 2008); agree on the role of central sensitization as a mechanism of 
hyperalgesia induction, but the mechanism by which this sensitization occurs is less 
clear. 
According to the 1990 American College of Rheumatology (ACR) classification criteria 
the diagnosis of fibromyalgia require tenderness on pressure in at least 11 of 18 
specified sites and the presence of widespread pain, defined as axial pain, left and right-
sided pain, and upper and lower segment pain (Wolfe F et al, 1990). 
In the last years, many objections have been expressed in relation to these criteria 
particularly because tender point count was rarely or incorrectly performed in primary 
care and the symptoms were not given the right consideration. Furthermore 
approximately 25% of FMS patients did not satisfy the ACR 1990 classification criteria 
even though they were considered to have fibromyalgia by their physicians. 
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The previous objections, together with the real need to find a common definition and 
classification for FMS, led Wolfe et al. in 2010 to propose simple, practical criteria for 
a clinical diagnosis of fibromyalgia. (Wolfe F et al, 2010) 
These new preliminary criteria had been thought to be suitable for use and did not 
require a tender point examination, providing instead a severity scale for characteristic 
fibromyalgia symptoms. 
The authors identified two variables that best defined fibromyalgia and its symptom 
spectrum: the widespread pain index and the composite symptom severity scale, a 
composite variable composed of physician-rated cognitive problems, unrefreshing 
sleep, fatigue and somatic symptoms. 
Furthermore, in 2011, Wolfe published a modification of the ACR preliminary 
Diagnostic Criteria for Fibromyalgia that allowed their use in epidemiologic and clinical 
studies without the requirement for an examiner. Practically, the author modified the 
symptom severity scale by substituting the somatic symptoms item with a 0–3 item that 
represented the sum of 3 items: headaches, pain or cramps in liver, abdomen or 
depression symptoms during the previous 6 months. However, it is important to remark 
that, although simple to use, the new criteria are not thought to be used for self-
diagnosis (Wolfe F et al, 2011). 
In summary we can say that in recent years the importance of symptoms other than pain 
has become very important in the assessment of the disease, in particular the presence of 
cognitive impairment is one of the three symptoms of the symptom severity scale. 
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2. Chronic fatigue syndrome 
Fatigue is a subjective feeling of low vitality, common in the community, with up to 
half of the general population reporting fatigue in large surveys. (Pawlikowska T., 1994) 
(Bates D., 1993) 
Complaints of fatigue are common in major chronic illness diseases (neoplasms, 
infections, etc) and are a significant component of rheumatologic disorders (Evans EJ., 
1999). Typically fatigue is transient and self-limiting, however, a minority of persons 
experience persistent and debilitating fatigue. When the fatigue cannot be explained by 
a medical condition it may represent chronic fatigue syndrome (CFS). CFS is a 
debilitating condition characterized by fatigue which, by exclusion, cannot be ascribed 
to another illness; it is defined as a persisted or recurrent condition of fatigue, that has 
lasted at least 6 months, not relieved by rest and resulting in a substantial reduction of 
previous levels of occupational, educational, social, or personal activities (Fukuda K. et 
al, 1994).  In addition to the chronic fatigue, widespread and persisyent pain is common 
in individuals with CFS. Other symptoms that are frequently present in CFS are 
headaches, recurrent sore throats, fever, muscle and joint pain and neurocognitive 
complaints.  
It is difficult to establish the prevalence of CFS, since it depends on the diagnostic 
criteria used and the study population; initial research suggested a prevalence between 
0.002% and 0.04%. However, latest epidemiological studies in the USA and in the 
United Kingdom show prevalence rates ranging from 0.007% to 2.5% of the general 
population.(Price R., 1992) (Jason LA., 1999) 
 
Despite more than a decade of research, the etiology and pathophysiology of CFS 
remains unknown. The onset is often sudden and precipitated by an infection, but in 
some patients, onset is more insidious and can be preceded by negative, stressful life 
events. The latter may explain the malfunctioning of the short-term (autonomic nervous 
system) and long-term (hypothalamus-pituitary-adrenal axis) stress response systems. 
(Nijs Jo, 2011) 
Many theories for the pathophysiology have been suggested, in particular: 
- the involvement of a bacterial or viral pathogen as the precipitating event in an 
immunogenetically vulnerable host 
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- the alterations of the immune system activity characterized by a defict in NK-cell lytic 
activity and an imbalance in cytokine production (Klimas NG., 1990) (Carlo-Stella N., 
2006) 
- the involvement of the hypothalamic pituitary adrenal axis having stress as a 
precipitating factor. (Narita M., 2003) 
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3. Central sensitisation 
 
Concerning studies on fibromyalgia, central sensitization and impaired descending 
pain modulation are generally accepted as the two major underlying mechanisms 
causing widespread hypersensitivity to pain (Staud R. and Rodriguez ME., 2006).  
Central sensitisation is defined as an increased central neuronal responsiveness. 
Several mechanism may lead to central sensitisation: 
(i) action potential windup, that results from repeated stimulation of afferents 
nerve fibers in the dorsal root 
(ii) expansion of receptor field, that results from activation of neurotransmitter 
receptor 
(iii) hyperexcitable neuronal response, that results from the release of substances 
that increase neuronal sensitivity (substance P, glutamate, aspartate) 
 (Dadabhoy D. et al, 2008;) 
 
The proposed neuroplastic changes that result from central sensitization have been 
visualized in FMS patients with functional magnetic resonance imaging (fMRI). 
Gracely and colleagues (Gracely RH, 2002) investigated fMRI changes in FMS patients 
and healthy controls while applying slow, controlled pressure to the thumb nail; FMS 
patients rated the experience as significantly more painful and demonstrated activation 
of significantly more pain related brain areas as compared to the controls. These data 
demonstrated the presence of brain neuroplastic changes. 
Furthermore, a PET study performed without noxious stimuli found a significant 
hyperperfusion in regions of the brain involved in the sensory dimension of pain 
processing, while hypoperfusion was noted in areas associated with the affective-
attentional dimension (Guedj E. et al., 2007). 
 
Moreover FMS is characterized by a dysfunction in descending pain inhibition (Vierck 
JCJ, 2006). Studies report low levels of the serotonin metabolite 5 hydroxy-indoleacetic 
acid (5HIAA) in the cerobrospinal fluid of FM patients and an overall dysfunction in 
serotonergic neurotransmission (Coaccioli S. et al., 2008). Serotonin plays an important 
role in modulating the descending inhibitory system.  
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Clinically central sensitisation is often manifested as hyperalgesia (exaggerated 
perception of painful stimuli) and allodynia (a perception of innocuous stimuli as 
painful) (Lidbeck J., 2002). Tender points are manifestations of allodynia. 
 
A direct evidence of assignment of CSF to a CNS disorder is still scarse even if 
symptoms like fatigue, non-refreshing sleep, concentration difficulties, impairments in 
short-term memory, and widespread pain are suggestive of CNS involvement. 
In the literature there are evidences that support the importance of widespread pain in 
CFS and often chronic pain is more disabling than chronic fatigue but only little 
progress has been made in understanding chronic widespread pain in patients with CFS. 
There are no direct evidence supporting the central sensitization hypothesis in CFS 
patients, but the present knowledge is suggestive of a central process similar to that seen 
in FMS, given the great overlap between the two diseases and the observed similarities. 
In fact hyperalgesia and lower pain thresholds are reported in patients with CFS and, 
similar to FM, the lack of peripheral tissue damage and the lack of a distinct localization 
of the pain complaints are suggestive of a central abnormality responsible for the 
chronic widespread pain. (Mira Meeus & Jo Nijs, 2007) 
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4. Neurocognitive impairment  
 
FMS and CFS are known to share many symptoms, which include pain - usually more 
pronounced in FM - and fatigue, together with mood, sleep and neurocognitive 
disorders.  
Symptoms as clouded mentation, forgetfulness and difficulty concentrating affect up to 
70% of patents and contribute to the overall disability of the disorders. These 
complaints are termed “fibrofog”. It is unclear whether this psychological “sensation” of 
abnormal cognitive ability has related objective changes in neurocognitive function in 
fact cognitive complaints may mark the presence of truly impaired cognitive 
functioning or they may represent the patient’s perception of impairment where none 
exists. (McCracken LM and Iverson GL, 2001). In this context, the evidence suggests 
chronic pain as the symptom more related to cognitive impairments, although there is 
little consensus on how pain brings about the observed decrement in cognitive function 
(Roth RS et al, 2005).  
However, clinical observations of self-reported cognitive deficits were confirmed by a 
study on 100 women with FMS and CFS demonstrating a 95% incidence of 
concentration difficulties and a 93% incidence of failing memory. Forgetfulness and 
concentrations problems were the fifth and sixth greatest problems reported after pain, 
fatigue, muscle tension or stiffness, and sleep problems (Zachrisson O et al, 2002). 
Fibromyalgia 
There are only a few studies that have specifically investigated neuropsychological 
issues in patients suffering from FMS and results remain heterogeneous, particularly it 
is unclear how much of the sensation of abnormal cognition in FM can be attribuited to 
objective dysfunction. 
Some studies have described significant cognitive deficits, mostly in working memory 
performance (Park DC., 2001, Leavitt F. and Katz RS., 2006); others studies have either 
failed to detect such differences (Walitt B., 2008) or found that differences between 
groups disappeared after correcting for fatigue, pain and depression (Suhr JA., 2003) 
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Park et al in 2001 analyzed three small groups of female subjects (23 FM, 23 healthy 
age-matched controls and 22 older adults) evaluating the following parameters: speed of 
information processing, working memory function, free recall, recognition memory, 
verbal fluency and vocabulary. Speed and working memory are the building blocks of 
cognitive function and predict long-term memory and reasoning. Speed of information 
processing is measured by how rapidly an individual can make simple mental 
operations, and working memory is measured by how much information a person can 
simultaneously store and process-it is an index of the “mental horsepower” that an 
individual brings to any given situations. Free recall is a measure of long-term memory 
and the ability to actively retrieve past episodic events. Recognition memory is the 
ability to recognize a previously studied item. Verbal fluency is the ability to quickly 
and efficiently retrieve information from their existing knowledge stores. In this study 
the authors reported memory and vocabulary deficits with intact processing speed in 
FM patients. 
In 2008 Walitt investigated the relations between objective cognitive function in FM 
using an automated neuropsychological assessment metrics (ANAM). ANAM is a 
computerized test of neurocognitive function that analyzes information processing, 
speed, complex attention, working memory and short-term memory. 27 FM patients, 27 
healthy controls and 18 muscoloskeletal pain patients were evaluated. No differences 
between subjects with pain disorder and pain-free controls were found concerning short-
term memory, cognitive efficiency, concentration and reaction time and no relation was 
found between FM symptoms severity and cognitive function. Moreover despite clinical 
improvement in FM patients after treatment there was no concomitant improvement in 
ANAM  performance.  
In contrast some existing data suggest that the influence of psychological variables such 
as depression, pain and fatigue, must be considered as factors contributing to 
neuropsychological presentation in FM. Suhr in 2003 suggested that most of the 
neuropsychological deficits found in FM can be explained by depression and fatigue, 
particularly depression was significantly related to memory performance and self-
reported fatigue was related to psychomotor speed. 
All these studies were done on small groups of patients and controls. 
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Chronic Fatigue Syndrome 
Cognitive complaints, as poor concentration, decreased memory for recent events and 
poor word-finding ability, are reported frequently also by CFS patients and these 
contribute considerably to their social and occupational dysfunction. Three major 
explanations have been considered in the literature which may contribute to cognitive 
dysfunctions in CFS:  
1) a CNS involvement,  
2) effect of subjectively experienced fatigue on performance,  
3) effect of psychopatological factors on performance.  
These explanations may possible interact. MRI studies demonstrated aspecific 
abnormalities in the cerebral white matter of CFS patients similar to patients with 
depression. 
In a review of Michiels 2001, the author showed that the most prominent findings in 
objective cognitive testing in CFS evidenced that information processing speed, 
learning and working memory are impaired and that CFS patients show intact 
performance on several aspects of attention and memory function. Moreover the 
evidence suggests that subjectively experienced fatigue is not related to cognitive 
performance.  (Michiels V.  and Cluydts R., 2001) 
Certainly many variables can influence neurocognitive functioning since FMS and CFS 
are commonly associated with both a number of co-morbidities and treatment factors 
that can adversely affect cognitive function, for example affective disorders, such as 
depression, anxiety, and panic, all of which are known risk factors for cognitive 
disorder among pain conditions (McCracken LM and Iverson GL, 2001; Roth RS et al, 
2005). 
Moreover, also disturbed sleep and excessive fatigue are known to correlate with 
cognitive impairment (Cote KA and Moldofsky H, 1997; Suhr AJ, 2003). 
Fortunately in the last decade the new technologies opened the way to the development 
of more sophisticated softwares for the assessment of neurocognitive disorders, thus 
allowing standardized and more objective evaluations (Gualtieri CT and Johnson LG, 
2006)
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5. The peptide β Amyloid   
The peptide β amyloid (Aβ) is the major constituent of amyloid plaques, and originates 
from the protein Amyloid Precursor Protein (APP). The majority of APP produced is 
degraded during the transport process on the cell surface. This is indicative of a fine 
regulation of the activity of this protein. The process of degradation of APP involves 
three enzymes: α, β and γ-secretase. The last two give way to the so-called 
"amyloidogenic pathway" that leads to the formation of the two isoforms Aβ 40 and Aβ 
42.  The literature shows that these two peptides are involved in neurodegenerative and 
psychiatric disorders. Amyloid-β is normally present in the brain, cerebrospinal fluid 
and peripheral blood.  In patients with Alzheimer’s disease, Aβ 42 aggregates and 
deposits in the brain, forming senile plaques that are one of the pathological hallmarks 
of the disease. 
In cerebrospinal fluid the concentration of Aβ 42 is reduced in patients with 
Alzheimer’s disease and in those with the mild cognitive impairment that precedes the 
disease, suggesting an association with selective deposition of Aβ 42  in the brain. 
(Andreasen N., 2001); most of the studies reported also an increase of Aβ 40 and Aβ 40/ 
Aβ 42 ratio. 
Some studies showed that patients suffering from mood disorder with multiple affective 
episodes present a greater risk for developing cognitive deficit and overt demential 
forms. (Kessing LV., Andersen PK, 2004) 
In particular literature data suggest that depression may increase the risk for 
Alzheimer’s disease; concerning depression, elevated plasma Aβ 42  levels and a lower 
Aβ 40/Aβ 42 ratio have been reported in patients with late-life depression, on the 
contrary lower plasma Aβ 42  levels and a higer Aβ 40/ Aβ 42 ratio have been reported 
in elderly individuals with depression. (Pomara N., 2006). 
In a study Baba et al showed a significantly higher serum Aβ 40/Aβ 42 ratio in patients 
affected by major depressive disease than controls in all age groups (young, middle-
aged and elderly) (Baba H., 2012) 
In a recent work pubblished by Piccinni et al, the authors underlined that the changes in 
plasma levels of different Aβ peptides might represent a useful tool to identify the risk 
for cognitive decline in bipolar patients confirming the presence of lower Aβ 42 levels 
and higher Aβ 40/ Aβ 42 ratio in patients respect to healthy subjects . They also 
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demonstrated a significant negative correlation between Aβ 42 levels and the duration 
of illness. (Piccinni A., 2012) 
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Chapter 2 : Objectives 
 
The aim of the study was to assess and compare neurocognitive disorders in FMS and 
CFS patients, also examining the influence that several clinical variables – i.e. pain, 
fatigue, mood and sleep disorders, drug assumption - have on the impairment of 
cognitive functioning, evaluated by means of a standardized and computerized test 
battery. We also assessed the levels of the two isoforms of Aβ amyloid (40 and 42) and 
their ratio and correlate this results with cognitive impairment investigated by an 
objective method. 
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Chapter 3 : Materials and methods  
 
Subjects 
40 patients affected by FMS (according ACR 1990 criteria (Wolfe F et al, 1990) and 45 
affected by CFS (according to Fukuda criteria of 1994 (Fukuda K. et al, 1994) were 
consecutively recruited from March 2010 to December 2011. Patients who were at least 
18 years old, could read and write Italian, and completed all measures for this study 
were selected. The Ethical Committee of the Azienda Ospedaliero-Universitaria Pisana 
approved all recruitment and assessment procedures. Eligible subjects provided written 
informed consent after receiving a complete description of the study and having an 
opportunity to ask questions. 
Measures 
All subjects provided information about demographic and clinical characteristics, 
medication use, and pain treatment history. Tender Points (TP) count was performed in 
each participants, and a TP index (TPi) was calculated according to a standardized 
procedure previously reported (Okifuji A et al, 1997). All patients completed the 
Fibromyalgia Impact Questionnaire (FIQ) (Burckhardt CS et al, 1991; Sarzi-Puttini P. 
et al, 2003), in which pain and fatigue severity and level of depression and anxiety were 
assessed with 10-cm visual analog scales, (0= “better” and 10= “worst”) and the health 
assessment questionnaire (HAQ)  evaluating the quality of life 
Fatigue was assessed also by means of the Functional Assessment of Chronic Illness 
Therapy-Fatigue Scale (FACIT) (Webster K. et al, 2003).  
Psychiatric diagnoses were made through the Structured Clinical Interview for the 
DSM-IV Axis I disorders (SCID-I/P) (First et al 1997), administered by psychiatrists. 
The following questionnaires were also administered: Self-raiting anxiety scale and the 
Self-raiting depression scale (SAS and SDS respectively) (Zung WW, 1971; Zung WW, 
1965). 
Finally, each subject was asked to refer the presence of sleep disorders, auto-referred 
complaints and the presence of memory and attention impairments following the onset 
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of the disease. Moreover, we considered the VAS from the FIQ asking if the patient felt 
rested upon awaking during the last week. 
All patients also completed the CNS Vital Signs©, a computerized neurocognitive 
assessment platform that enables the objective evaluation and characterization of 
patients neurocognitive function. This test battery is well validated and a large amount 
of scientific papers concerning its use in different diseases have been published. It is 
comprised of seven tests: verbal and visual memory, finger tapping, symbol digit 
coding, the Stroop Test, a test of shifting attention and the continuous performance test. 
The neurocognitive index (NCI) is an average score derived from the domain scores or a 
general assessment of the overall neurocognitive status of the patient.  
These scores are auto‐scored using an algorithm based on a normative data set of 1900+ 
subjects, ranging from ages 8 – 90, that represents the “average” score (Gualtieri CT 
and Johnson LG 2006). The test battery lasts approximately 30 minutes. The exercises 
included in the software are: 
Verbal memory (VBM). Fifteen words are presented, one by one, on the screen 
every two seconds. For immediate recognition, the participant has to identify those 
words nested among fifteen new words. Then, after six more tests, there is a delayed 
recognition trial. This test measures verbal learning, memory for words, word 
recognition and immediate and delayed recall. 
Visual memory (VIM). This test is analogue to the previous, except for the fact that 
geometric figures are presented. This test measures visual learning, memory for 
geometric shapes, geometric shapes recognition, immediate and delayed recall. 
Finger tapping test (FTT). This test requires athletes to press the Space Bar with 
their right index finger as many times as they can in 10 seconds. They do this once for 
practice, and then there are three test trials. The test is repeated with the left hand. This 
test measures motor speed and fine motor control. 
Symbol Digit Coding (SDC). This test consists of serial presentations of screens, 
each of which contains a bank of eight symbols above and eight empty boxes below. 
The participant types in the number that corresponds to the symbol that is highlighted. 
With this test information processing speed, complex attention, visual‐perceptual speed 
and information processing speed are evaluated. 
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Stroop test (ST). It consists of three parts. In the first part, the words RED, 
YELLOW, BLUE, and GREEN (printed in black) appear at random on the screen, and 
the participant presses the space bar as soon as the athlete sees the word. In the second 
part, the words RED, YELLOW, BLUE, and GREEN appear on the screen, printed in 
color. The participant is asked to press the space bar when the color of the word 
matches what the word says. In the third part, the words RED, YELLOW, BLUE, and 
GREEN appear on the screen, printed in color. The participant is asked to press the 
space bar when the color of the word does not match what the word says. With this test 
it is possible to assess executive function, simple and complex reaction time, 
speed‐accuracy trade‐off, information processing speed and inhibition/disinhibition. 
Shifting Attention (SAT) test. It is a measure of ability to shift from one instruction 
set to another quickly and accurately. Participants are instructed to match geometric 
objects either by shape or by color. Three figures appear on the screen, one on top and 
two on the bottom. The top figure is either a square or a circle. The bottom figures are a 
square and a circle. The figures are either red or blue (mixed randomly). The participant 
is asked to match one of the bottom figures to the top figure. The rules change at 
random (i.e., match the figures by shape, for another, by color). This test evaluates 
executive function (shifting sets), reaction time, information processing speed, and 
speed‐accuracy trade‐off. 
Continuous Performance (CPT). It is a measure of vigilance or sustained attention 
or attention over time. The athlete is asked to respond to the target stimulus “B” but not 
to any other letter. The stimuli are presented at random. With this test sustained 
attention, choice reaction time, and impulsivity are measured. 
The domains analyzed in the test are described in table 1. 
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CLINICAL 
DOMAINS 
CLINICAL DOMAIN DESCRIPTION 
Neurocognitive 
Index (NCI) 
Measure: An average score derived from the domain scores or a general 
assessment of the overall neurocognitive status of the patient.  
Relevance: Summary views tend to be most informative when evaluating 
a population, a condition category, and outcomes. 
Composite 
Memory 
Measure: How well subject can recognize, remember, and retrieve 
words and geometric figures.  
Relevance: Remembering a scheduled test, recalling an appointment, 
taking medications, and attending class. 
Verbal 
Memory 
Measure: How well subject can recognize, remember, and retrieve 
words. Relevance: Remembering a scheduled test, recalling an 
appointment, taking medications, and attending class. 
Visual 
Memory 
Measure: How well subject can recognize, remember and retrieve 
geometric figures.  
Relevance: Remembering graphic instructions, navigating, operating 
machines, recalling images, and/or remember a calendar of events. 
Processing 
Speed 
Measure: How well a subject recognizes and processes information i.e., 
perceiving, attending/responding to incoming information, motor speed, 
fine motor coordination, and visual‐perceptual ability.  
Relevance: Ability to recognize and respond/react i.e., fitness‐to-drive, 
occupation issues, possible danger/risk signs or issues with accuracy and 
detail. 
Executive 
Function 
Measure: How well a subject recognizes rules, categories, and manages 
or navigates rapid decision making.  
Relevance: Ability to sequence tasks and manage multiple tasks 
simultaneously as well as tracking and responding to a set of 
instructions. 
Psychomotor 
Speed 
Measure: How well a subject perceives, attends, responds to 
visual‐perceptual information, and performs motor speed and fine motor 
coordination.  
Relevance: Ability to perform simple motor skills and dexterity through 
cognitive functions i.e., use of precision instruments or tools, performing 
mental and physical coordination i.e., driving a car, playing a musical 
instrument. 
Reaction 
Time 
Measure: How quickly the subject can react, in milliseconds, to a simple 
and increasingly complex direction set.  
Relevance: Driving a car, attending to conversation, tracking and 
responding to a set of simple instructions, taking longer to decide what 
response to make. 
Complex 
Attention 
Measure: Ability to track and respond to information over lengthy 
periods of time and/or perform mental tasks requiring vigilance quickly 
and accurately. Relevance: Self‐regulation and behavioral control. 
Cognitive 
Flexibility 
Measure: How well subject is able to adapt to rapidly changing and 
increasingly complex set of directions and/or to manipulate the 
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information. Relevance: Reasoning, switching tasks, decision‐making, 
impulse control, strategy formation, attending to conversation. 
Table 1 CNS Vital Signs
©
 domains and their descriptions. 
 
Subsequently in a subgroup of 25 FMS and 25 CFS patients the levels of beta amyloid 
were evaluated  using a commercial ELISA kit (Invitrogen Inc) and compared with 25 
age and sex matched healthy controls  
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Statistical analysis 
The statistical analysis of differences between the two groups was performed using the 
two-tailed T-test. The correlations between two variables were determined by using 
linear regressions and Pearson correlations. Also a multivariate analysis was performed 
in order to adjust comparison for independent variables (age, sex, illness duration and 
pain perception), that varied between the two groups of patients. The comparison 
between dichotomous variables was performed by means of the Chi-squared test. In 
order to establish a coefficient of concordance between neurocognitive disorders 
complained and established by the CNS Vital Signs
©
, the contingency analysis was 
performed. Significance for the results was set at p < 0.05. All statistical analyses were 
carried out using the Graph Pad Prism 5.0 and SPSS 14.0 softwares 
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Chapter 4 : Results 
 
The demographic characteristics of patients recruited are summarized in Table 2. 
FMS and CFS were significantly different in terms of age and sex (p=0,001 and 
p=0,0001 respectively), in accordance with the literature (Neumann L. and Buskila D., 
2003)  
 
 FMS CFS p 
N 40 45 - 
gender  97.5% women 51,1% women <0.001 
age (y); mean (SD) 46.6 (10,5) 38.5 (11.8) 0.001 
race/ethnicity 100% Caucasian 100% Caucasian - 
education (y); mean (SD) 12.7 (4.2) 14.2 (3.1) 0.062 
employment status (%)    
managerial/office 25.0 35.6 0,413 
skilled labor 12.5 15.6 0,927 
semiskilled labor 10.0 11.1 0,852 
students 2.5 15.6 0,092 
homemaker 10.0 0.0 0,097 
retired 22.5 4.4 0,031 
unemployed 17.5 17.8 0,801 
 
Table 2 Demographic characteristics 
 
FMS and CFS patients did not differ by race and years of education but about 
employment status, a  prevalence of retired people is present in FMS group, that 
depended of the higher mean age. About 18% of both FMS and CFS patients was 
unemployed and most of them referred to have left work because of the disease. 
Concerning co-morbidity we analyzed only the presence of autoimmune thyroiditis and 
no difference was found in the two groups (27% in FM vs 29% in CFS, p 0,93). 
Clinical characteristics of the disease, questionnaire scores and scales are shown in 
Table 3 
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 FMS CFS p 
illness duration (y); mean (SD) 9.8 (6.8) 6.4 (5.1) 0.004 
Tender Points;  mean (SD)    
N 16.2 (2.5) 8.1 (7.4) <0.001 
TPi 6.8 (1.5) 2.9 (2.7) <0.001 
FIQ;  mean (SD) 62.8 (13.3) 55.5 (20.4) 0.064 
FACIT;  mean (SD) 27.6 (8.6) 30.5 (10.0) 0.167 
VAS pain;  mean (SD) 7.1 (2.3) 3.5 (3.0) <0.001 
VAS fatigue;  mean (SD) 8.0 (2.3) 7.7 (2.0) 0.474 
HAQ; mean (SD) 0,76 ± 0,57 0,41 ± 0,42 0,005 
VAS anxiety 5.9 (2.0) 5.0 (2.6) 0.102 
VAS depression 4.3 (2.4) 3.8 (3.2) 0.461 
SAS;  mean (SD) 44.8 (9.5) 41.6 (8.2) 0.110 
SDS;  mean (SD)  46.5 (8.3) 45,1 (8.4) 0.465 
cognitive impairments complained (%) 85.0 84,4 0.817 
concentration yes/no (%) 80.0 82,2 0.987 
memory yes/no (%) 57.5 64,4 0.665 
Sleep disorders complained    
sleep disorder yes/no (%) 85.0 82,2 0.959 
VAS restful sleep; mean (SD) 7.7 (2.5) 7.4 (2.1) 0.368 
    
 
Table 3 Clinical characteristics, questionnaire scores and visual analogue scales 
 
FMS patients had a longer duration of illness compared to CFS patients (p=0.004). FMS 
patients showed a higher number of TP and TP index (p<0.0001) and a higher value of  
pain (p<0.0001) and it is in agreement with the definitions of the disease. 
A significant difference was found about HAQ which is higher in FMS patients 
(p=0,005) to suggest that they have a poorer quality of life. No difference was found 
between the two groups with respect to fatigue (evaluated by means of VAS scale and 
FACIT ). 
No statistically significant difference was also found for auto-referred feelings of 
anxiety and depression (assessed with visual scales and questionnaires SAS and SDS), 
cognitive impairments complained (concentration and memory) and sleep disorders. 
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No difference was found concerning ANA positivity in the two groups (36,6% in FMS 
vs 41,3% in CFS, p 0.917). 
Concerning drug assumption, no statistically significant difference was found between 
FMS and CFS patients, even if FM patients used more drugs, in particular opioids, than 
CFS, as shown in Table 4. 
 
Drug FMS % CFS % p 
NSAIDs 15,0 11,1 0,834 
Benzodiazepines 22,5 20,0 0,988 
SSRI 20,0 20,0 0,786 
SNRI 7,5 11,1 0,844 
tricyclic antidepressants 2,5 6,7 0,695 
Opioids 10,0 0,0 0,097 
Steroids 0,0 4,4 0,527 
muscle- relaxants 22,5 13,3 0,411 
Anticonvulsants 22,5 11,1 0,263 
antidepressants* 30,0 33,3 0,923 
drugs** 57,5 53,3 0,827 
 
Table 4 Comparison of drug assumption between FMS 
and CFS patients (NSAIDs, non steroidal anti-
inflammatory drugs; SSRI, selective serotonin reuptake 
inhibitors; SNRI, serotonin noradrenalin reuptake 
inhibitors). * SSRI + SNRI + tricyclic antidepressants; ** 
patients who assumed at least one drug. 
 
Psychiatric comorbidity 
No difference was observed between FMS and CFS patients in terms of axis-I 
psychiatric disorders, assessed by means of SCID-I (Table 5). The prevalent psychiatric 
condition in both groups was a lifetime (LT) disorder characterized by generalized 
anxiety (GAD) and panic attacks (PD). Bipolar type-II disorder (BD II) was instead 
observed in a larger number of CFS patients (17.78%) as a lifetime condition compared 
to FMS patients (2.50%), although the difference was not statistically significant 
(p=0.053). Only one CFS patient and none of the FMS patients, still had a BD II 
disorder at the observation time. Small percentages of patients from both groups 
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resulted to have psychiatric LT or current disorders such as depression (D; 10.00% LT 
and 5.56% current in FMS versus 8.89% and 2.22% in CFS), LT eating disorders such 
as anorexia and bulimia (ED; 2.50% in FMS and 4.44% in CFS), and current obsessive-
compulsive disorder (OCD; present only in 1 FMS patients, 2.50%). 
 
LT (%) current (%) 
  FMS CFS p FMS CFS p 
GAD/PD 37.50 20.0 0,12 11,11 6.7 0,817 
D 10.00 8.9 0,79 5.56 2.2 0,917 
BD II 2.50 17.8 0,053 0.00 2.2 0,953 
ED 2.5 4.4 0,92 0.00 0.0 - 
OCD 2.5 0.0 0,95 2.5 0.0 0,953 
 
Table 5 Lifetime (LT) and current psychiatric 
comorbidity assessed by SCID-I (DSM-IV) (GAD, 
generalized anxiety disorder; PD, panic disorder; D, 
depression; BD II, bipolar disorder II; ED, eating 
disorders; OCD, obsessive-compulsive disorder). 
 
Neurocognitive functioning assessment 
As assessed by CNS Vital Signs© test battery, FMS patients resulted to have more 
compromised neurocognitive function compared to CFS patients.  
The neurocognitive index (NCI) was lower in FMS than in CFS patients (p=0.0032), 
particulary single items such as visual memory (ViM; p=0.0039), processing speed 
(PrS; p=0.02), executive function (EF; p=0.001), psychomotor speed (PsS; p<0.0001) 
and cognitive flexibility (CF; p=0.0011) were lower in FMS compared to CFS patients. 
Since FMS and CFS patients differed in terms of age, sex, disease duration and pain 
perception (VAS pain and TPi), also multivariate analysis was performed in order to 
adjust results for all possible confounders (table 6)  (figure 1). 
Furthermore, no difference was found within CFS group between male and female sex. 
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Figure 1 Comparison of CNS Vital Signs
© 
mean standard scores between FMS and 
CFS patients (standard scores ranges: >110=above; 110-90 (light-green)=average; 89-
80 (yellow)=low average; 79-70 (orange)=low; <70 (red)=very low). 
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FMS CFS p 
adjusted 
p 
Neurocognitive index (NCI) 74,48 (21,60) 89,09 (22,65) 0.0032 0.036 
Composite memory (CM) 87,30 (18,33) 93,67 (17,13) 0.1016 0.071 
Verbal memory (VeM) 88,18 (20,84) 89,09 (21,26) 0.8422 ns 
Visual memory (ViM) 91,38 (14,38) 100,5 (13,88) 0.0039 0.027 
Processing speed (PrS) 79,28 (19,88) 88,58 (16,37) 0.02 0.047 
Executive function (EF) 70,93 (33,62) 93,22 (25,20) 0.001 0.036 
Psychomotor speed (PsS) 61,85 (34,69) 89,96 (22,75) <0.0001 0.012 
Reaction time (RT) 89,83 (19,42) 94,31 (21,88) 0.3229 ns 
Complex attention (CA) 64,03 (45,55) 75,53 (74,02) 0.3976 ns 
Cognitive flexibility (CF) 69,75 (34,10) 91,98 (26,27) 0.008 0.032 
 
Table 6 mean CNS vital signs scores (SD). (ns, not significant). 
 
Neurocognitive function correlated with the duration of illness. In particular, duration of 
illness negatively correlated with NCI (r=-0.23; p=0.034), ViM (r=-0.28; p=0.0099) and 
PsS (r=-0.45; p<0.0001) (see Figure 2A).  
NCI did not correlate with any clinical parameters, although in CFS group EF 
negatively correlated with FIQ (r=-0.36; p=0.016) and FACIT (r=-0.30; p=0.048), and 
CF negatively correlated with FIQ (r=-0.318; p=0.035) and FACIT (r=-0.374; p=0.011). 
In FMS group instead ViM negatively correlated with VAS pain (r=-0.475; p=0.008) 
and with FIQ (r=-0.374; p=0.042). 
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Figure 2 A) Negative correlation between illness duration and NCI.  
               B) Negative correlation between VAS pain and NCI. 
 
Moreover, considering the two groups together, also VAS pain was found to negatively 
correlate with NCI standard score (p=0.0046; r=-0.31) and with single items of the CNS 
vital signs, such as ViM (p=0.0066; r=-0.30), PrS (p=0.008; r=-0.29), EF (p=0.01; r=-
0.28), PsS (p=0.007; r=-0.30), and CF (p=0.007; r=-0.30) (see Figure 2B). On the 
contrary, VAS fatigue was not found to correlate with any item of the CNS Vital 
Signs
©
. However, when the two groups were considered separately, the significant 
negative correlation of VAS pain and neurocognitive disorders was lost, both in FMS 
and in CFS groups. This finding is probably due to the fact that, within each group of 
patients, VAS pain scores did not spread on the entire scale, while when patients were 
taken together, we could observe a wider range of VAS pain scores. Furthermore, while 
in FMS patients VAS pain correlated with VAS fatigue (p=0.003; r=0.47), in CFS 
patients did not. 
Neurocognitive standard scores were also analyzed by comparing both FMS and CFS 
patients with a psychiatric disorder versus those who had not. In particular, we found 
statistically significant differences between patients who had or had not a lifetime 
psychiatric disorder in terms of NCI (mean ± SD: 75.0±25.8 vs 90.3±16.8; p=0.002), 
PrS (mean ± SD: 80.4±19.1 vs 88.5±17.3; p=0.043), EF (mean ± SD: 76.0±34.6 vs 
90.2±25.7; p=0.036), PsS (mean ± SD: 68.2±35.8 vs 86.3±24.3; p=0.008), CF (mean ± 
SD: 74.1±35.4 vs 89.9±25.7; p=0.022). The more impaired function in patients with a 
lifetime psychiatric disorder was psychomotor speed, whose mean standard score was 
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well under the range of normality (very low score), while the other functions seemed to 
be less impaired. As for presence of a current psychiatric disorder, no difference was 
instead observed between patients who had and patients who had not. 
Further analysis showed that neurocognitive function, measured with the NCI, also 
differ between patients assuming or not antidepressants (p=0.015), particularly in terms 
of complex attention (p=0.008), which decreased well under the normality range in 
patients taking antidepressants (mean ± SD: 44.07 ± 94.81 and 82.24 ± 33.58 
respectively). Considering instead patients under one or more pharmacological 
treatments versus patients not treated at the observation time, the only difference 
highlighted was related to processing speed (PrS), which was slightly lower in patients 
assuming drugs (p=0.04).  
Finally we calculated the k-coefficient of concordance between complained (subjective) 
and objective neurocognitive disorders in both group of patients. We found in both 
groups a lack of concordance between complained and real deficits, although in CFS the 
difference resulted more marked, as shown in Table 7.  
 
 
 
 
 
Table 7 Analysis of complained versus real neurocognitive impairments 
 
 
 
 
 
  FMS CFS 
NCD subjective % 85.0% 84.4% 
NCD objective % 42.5% 22.2% 
concordant 21/40 15/45 
k-coefficient  0.0082 -0.009 
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Beta amyloid 
In a subgroup of 25 FMS and 25 CFS patients we analyzed levels of β amyloid (Aβ ) 40 
and 42 and then we compared these results with a sample of 25 healthy subjects (HC). 
Demographic and clinical characteristics of our cohort are showed in table 8 and 9. 
We observed a difference in gender, with a prevalence of male in CFS group, no 
differences was found concerning age and onset of disease.  
 
 
 
FM 
(n=25) 
CFS 
(n=25) 
HC 
(n=25) p 
Age 
(year mean ± SD) 
 
43.44±9.57 
 
38.47 ±11.13 
 
41.66 ± 10.52 
 
Sex 
(male:female) 
1:24 15:10 10:15 <0.05 
Disease duration 
(years ± SD) 
10.04 ± 7.37 7.8 ±5.25 NA  
 
Worker status 
6 unemployed 
3 retired 
16 employed 
5 unemployed 
1 retired 
19 employed 
0 unemployed 
0 retired 
25 employed 
 
 
Table 8: patients and control demographics characteristics; in the p column we showed 
the differences between the groups. 
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FM 
(n=25) 
CFS 
(n=25) 
p 
FIQ 61.98 ± 12.93 51.35 ± 23.85 Ns 
VAS pain 6.6 ± 2.36 2.47 ± 2.90 *** 
VAS fatigue 8.24 ± 1.66 7.47 ± 2.90 NS 
FACIT 27.80 ± 9.09 30.13 ± 11.37 NS 
Tender points 15.84 ± 2.62 2.45 ± 3.06 *** 
CNS_NCI 73.76 ± 20.56 93.20 ± 17.94 NS 
Referred cognitive 
impairment 
22 patients 20 patients NS 
Mood disturbance 
10 lifetime 
4 current 
10 lifetime 
1 current 
NS 
 
Table 9: clinical characteristics of  patients and healthy volunteers  
 
 
The levels of Aβ 40 and Aβ 42 and Aβ 40/ 42 ratio were showed in table 10. We did not 
observe any difference in Aβ 40, Aβ 42 and their ratio in our population. Moreover we 
did not find any correlation between Aβ40 and Aβ42 levels and all cognitive domains 
assessed by CNS vital signs© in patients and controls. No difference in Aβ levels was 
found concerning psychiatric co-morbidities.  
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A
pg/ml) 
A
pg/ml) 
A A 
FM 20,35±11,37 4,25±0,72 4,72±2,32 
CFS 18,30±11,91 4,25±0,86 4,18±2,37 
HC 19,46±13,41 4,40±1,14 4,57±3,19 
 
Table 10: Aβ 40 and 42 and their ratio in patients and controls 
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Fig 1: graph representation of level of Aβ 40, Aβ 42 and Aβ 40/ Aβ 42 in our 
population: no significant differences were found 
 
In the FM group we found a statistically significant negative correlation between 
Aβ40/42 ratio and disease duration (p=0.0056; r= - 0,53). In the FM group we found a 
statistically significant negative correlation between Aβ40 levels and FIQ values 
(p=0.037; r=-0.42) and FACIT scores (p=0.0069; r=-0.52). Moreover in FM we found a 
negative correlation between Aβ42 levels and age (p=0,03, r= -0,43). 
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Chapter  5 : Discussion  
 
Patients with chronic pain often complain of difficulties with cognitive functioning. 
Chronic pain is commonly associated with both a number of co-morbidities and 
treatment factors that can adversely affect cognitive function. For example affective 
distress, depression, anxiety, disturbed sleep and fatigue are known risk factors for 
cognitive disturbance. Cognitive complaints may mark the presence of truly impaired 
cognitive functioning or they may represent the patient’s perception of impairment 
where none exists. 
Accumulating evidence indicates that a number of chronic pain and stress-related 
disorders, including chronic low back pain, FMS and CFS, are characterized by changes 
in brain morphology, in particular gray matter reductions (Apkarian AV et al, 2004; de 
Lange FP et al, 2005; Kuchinad A. et al, 2007) and abnormal cerebral perfusion 
(MacHale SM., 2000). In FMS patients, gray matter loss occurred mainly in regions 
related to stress (parahippocampal gyrus) and pain processing (cingulated, insular and 
prefrontal cortices) and the changes in these systems could contribute to the 
maintenance of pain and appears consistent with cognitive deficit characteristic of FMS 
(Kuchinad A et al, 2007). Moreover Kuchinad and colleagues (2007) found that FMS 
patients have brain gray matter atrophy with a yearly decrease in gray matter volume 
more than three times than that of age-matched controls. Concerning CFS some 
magnetic resonance imaging (MRI) studies have detected significantly more 
abnormalities in the subcortical white matter of chronic fatigue syndrome subjects, 
compared to healthy or trauma comparison subjects (Sullivan PF, 2000), while in other 
MRI studies the results for subjects with this syndrome did not differ from those for 
healthy or depressed subjects (Cope H., 1996). In addition, MRI abnormalities have not 
been associated with neurocognitive performance (Cope H., 1995). Other studies using 
single photon emission computed tomography (SPECT) scans have found that CFS 
patients have lower levels of regional cerebral blood flow throughout the brain, 
compared to healthy subjects. CNS perfusion abnormalities, typically hypoperfusion, 
also have been found more often on SPECT scans in these patients than in healthy or 
depressed comparison subjects, although no specific anatomic pattern has emerged and 
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the effect of co-morbid major depression is difficult to ascertain (Ichise M, 1992). 
Moreover some studies showed that an abnormal cerebral perfusion pattern is present in CFS 
subjects non depressed and that is it similar but not identical to those in patients with depressive 
illness. (MacHale SM,  2000). Conversely, a recent rigorously controlled study detected no 
difference in cerebral blood flow between twins with chronic fatigue syndrome and their 
healthy co-twins (Lewis D., 2001). Overall, MRI and SPECT studies are generally 
consistent in demonstrating some abnormalities in chronic fatigue syndrome patients. 
However, the functional significance and clinical utility of these findings remain 
uncertain. 
The results of the present study showed the importance of chronic pain in 
neurocognitive impairments in FMS and CFS patients, as resulted by the correlation of 
neurocognitive index and other CNS Vital Signs© domains with VAS pain and illness 
duration, as well as by a worse impairment in FMS compared to CFS patients.  
No difference was observed between FMS and CFS patients in terms of axis-I 
psychiatric disorders and thank to these observations we can suppose that, at least in our 
cohort of patients, neurocognitive functioning should be independent of psychiatric 
comorbidity.  
Unlike other studies (McCracken, 2001; Roth RS, 2005; Suhr JA, 2003) we did not find 
any correlation between neurocognitive impairment and depression and fatigue (both 
assessed by VAS) although some neurocognitive items –in particular psychomotor 
speed- were lower in patients with a lifetime psychiatric disorder compared to patients 
without. The absence of correlation with depression is probably related to the small 
number of depressed patient in our cohort. 
Moreover, concerning the frequently found prevalence of neurocognitive impairments 
in female gender - reported by the previously mentioned authors - our data suggested 
instead that in FMS and CFS patients gender did not influence neurocognition, since the 
gender-adjusted multivariate analysis still remained significant, and no difference was 
highlighted by comparing male and female patients within CFS group. However, unlike 
these studies, in the present one neurocognitive functioning was assessed by means of 
computerized system, more objective and accurate in evaluating every single ability. 
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We have already shown in Figure 1 how evident is the neurocognitive function 
impairment in FMS patients, in particular, FMS patients, aside from the NC index, 
which is only a composite index that globally indicate how compromised are cognitive 
faculties, reported very low standards score - listed in order of severity- in psychomotor 
speed, complex attention (low also in CFS), cognitive flexibility, executive functioning, 
and processing speed (low). 
Psycomotor speed means being able to coordinate thinking fast with doing something 
fast i.e., use of precision instruments or tools, performing mental and physical 
coordination i.e., driving a car, playing a musical instrument. A deficit in complex 
attention make instead problematic the performance of mental tasks that require 
vigilance, quickly and accurately Cognitive flexibility is the ability to switch behavioral 
response according to the context of the situation, for example an impaired in this 
function can cause difficulties in reasoning, switching tasks, decision‐making, etc… 
Executive functioning is the ability to sequence tasks and manage multiple tasks 
simultaneously, as well as tracking and responding to a set of instructions. Finally, 
processing speed involves the ability to automatically and fluently perform relatively 
easy or over-learned cognitive tasks, especially when high mental efficiency is required. 
Unlike the literature we showed  a slow information processing speed in FMS compared 
to CFS (Glass JM, 2008). These results are obviously insufficient to justify such a 
discrepancy, nevertheless it is reasonable to emphasize that, despite the other studies, 
information processing speed was here assessed with a computerized procedure which 
calculated the scores coming from several different exercises (i.e. symbol digit coding, 
Stroop and shifting attention tests). 
Of particular interest are the negative correlations of EF, CF and ViM with FIQ, FACIT 
and VAS scales whose values increase together with disease severity. CFS patients who 
had a more severe disease (higher FIQ and FACIT scores) also had more impaired 
executive function and cognitive flexibility, confirming the possibility of a dysfunction 
at prefrontal level, as reported by neuroimaging studies  (MacHale SM et al, 2000). 
FMS patients who had more severe disease (higher FIQ and VAS pain) reported instead 
poor performance in terms of visual memory, suggesting the possible involvement of 
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brain areas such as medial temporal lobe and occipital cortex in the pathophysiology of 
the syndrome (Khan ZU et al, 2011). 
Globally considering the reported findings, in FMS patients attention and concentration 
generally seemed more compromised than memory and it is in accordance with the 
recent literature in fact several writers have invoked the role of disturbed attentional 
process to explain the adverse impact of chronic pain on cognitive function. (Glass JM, 
2006). 
It is important to underline that complex attention was found reduced by the use of 
antidepressants (SSRI, SNRI and/or tricyclic compounds), as previously reported also 
by McCracken and colleagues (2001). Processing speed instead seemed to be more 
impaired in patients who were assuming at least one drug among those which are 
normally prescribed for the treatment of FMS and CFS. Further investigations on the 
relationship between neurocognitive disorders and drugs commonly prescribed for the 
treatment of FMS - and also on the link among the various affective disorders - could be 
useful to understand if the impairment of neurocognitive function could be at least 
partially ascribed to the use of some of these ones. However that fact that no difference 
was found in pharmacological therapies between FMS and CFS patients let us suppose 
that the neurocognitive impairment in FMS is not due to assumed drugs.  
It is interesting that FMS patients were more compromised but less frequent aware of 
their cognition problems on the contrary CFS patients usually complained without 
having a real deficit. A possible explanation of the this observation could be related to 
personality traits of CFS patients, such as self-criticism and perfectionism (Kempke S. et 
al, 2011), which can lead to excessive worries about their performance (e.g., concern 
over mistakes and doubt about actions).  
 
Another important aspect highlighted by the present research is the one concerning the 
relation between β amyloid levels and cognitive impairment. Actually, there are not 
validated biomarkers of these diseases, in particular for FMS which is a common 
disease, (Bazzichi L., 2010) and many researchers tried to found a putative 
biomarker.(Ang DC, 2011; Heidari B., 2010; Bazzichi L, 2010). Since literature data 
showed a relation between β amyloid levels and cognitive deficit (Kessing L.V., 
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Andersen PK, 2004), the second aim of this study was to evaluate for the first time the 
levels of these peptides in FMS and CFS patients in order to find a possible correlation 
with objective cognitive impairment evaluated by a standardized methods. In the 
literature Aβ peptides was found altered in many conditions, such as mild cognitive 
impairment (MCI) and Alzheimer disease (AD) (Graff-Radford NR, 2007). No data are 
available in literature concerning the levels of these peptides in FMS and CFS patients. 
The present study showed a normal levels of Aβ in the serum of FMS and CFS patients. 
The cognitive impairment referred by FMS and CFS patients don’t correlate with the 
Aβ levels. Also the cognitive impairment evaluated by CNS vital signs, don’t correlate 
with the amyloid peptides. These observations suggest that the cognitive impairment 
referred by the patients, was probably related to the health status, instead of a damage of 
central nervous system. In contrast with literature, we did not find any differences in 
patients concerning psychiatric comorbidities, in particular depression. These 
observation is probably related to the small number of depressed patient in our cohort 
(only 5 patients). 
The observation of normal levels in Ab42 suggest a non-improvement FMS related in 
AD development. However the correlation between Ab40 levels and disease duration, 
FIQ and FACIT, suggest a  possible alteration in Amyloid metabolism, related to 
Fibromyalgia and this observation might suggest a relationship with chronic pain. 
Further studies are necessary to confirm these data, in particular to understand the CNS 
structures involved in FM. 
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Chapter 6 : Conclusions 
  
The main findings of the present work have been:  
1) the more elevated prevalence of neurocognitive disorders in FM than in CFS 
patients, despite the more frequent complaint of the latter;  
2) the tight relation between neurocognitive impairments and chronic pain, which is 
independent of psychiatric comorbidity.    
3) the lack of correlation between cognitive impairment and Aβ levels 
4) the possible alteration in Amyloid metabolism in FMS related in particular to disease 
duration, FIQ and FACIT 
Concerning neurocognitive impairments in FMS patients compared to CFS patients, we 
demonstrated that this kind of disorder - in particular attention and concentration 
deficits - is prevalent in FMS patients and it is mainly related to chronic pain conditions. 
Moreover, CFS patients seemed more frequently complained about memory and 
attention difficulties without having a severe impairment. 
However, in these diseases, it is important not to underestimate attention and memory 
disorders complained by patients, because they contribute to the disability of the 
disorders and could disclose a more severe condition affecting the CNS, including a 
decreased gray matter density. 
 
. 
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